Cannabis and Autism: What Families Are Trying and What Research Shows

Special Populations

20:1 CBD:THC

Israeli clinical studies show CBD-rich cannabis may reduce self-injury and agitation in children with severe autism, but safety concerns about cannabinoid effects on developing brains remain unresolved.

Aran et al., Journal of Autism and Developmental Disorders, 2021

Aran et al., Journal of Autism and Developmental Disorders, 2021

View as image

Few topics in cannabinoid medicine carry more emotional weight than cannabis and autism. The families involved are often desperate. They are dealing with severe behavioral challenges, including self-injury, aggression, property destruction, and sleep disturbance, that profoundly impact the quality of life of both the child and the entire family. Conventional medications for these behaviors, primarily antipsychotics like risperidone and aripiprazole, carry significant side effects including weight gain, metabolic syndrome, and tardive dyskinesia. Many families have tried multiple medications with limited success.

Cannabis, particularly CBD-rich products, has emerged as a treatment that some families are finding helpful. The evidence is preliminary. The ethical questions are complex. But the experiences of families and the emerging research data cannot be dismissed.

Why Families Are Turning to Cannabis

The primary driver is inadequate options. Autism spectrum disorder (ASD) affects approximately 1 in 36 children in the United States. While the core features of autism, differences in social communication and restricted or repetitive patterns of behavior, are not targets for medication, the associated behavioral and psychiatric symptoms often are.

Irritability, aggression, and self-injurious behavior are among the most distressing features of severe autism. These behaviors are dangerous to the child and to caregivers. They are frequently the reason families seek residential placement. Two medications, risperidone and aripiprazole, are FDA-approved for irritability associated with autism, but they carry significant side effects. Weight gain of 5 to 10 pounds in the first few months is common. Metabolic syndrome, including elevated blood sugar and cholesterol, develops in a meaningful percentage of patients. Sedation, tardive dyskinesia (involuntary movements), and hormonal effects are additional concerns.

Sleep disturbance affects an estimated 40 to 80 percent of children with autism and contributes to behavioral problems during the day. Sleep medications approved for pediatric use are limited, and melatonin, while helpful for some, does not solve the problem for many.

Against this backdrop, families who learn about cannabis, particularly CBD, from other parents, social media, or advocacy groups are willing to try it. The motivation is not recreational or frivolous. It is born from exhaustion and limited alternatives.

The Israeli Studies: What They Show

Israeli Research

Cannabis & Autism: Study Outcomes

Parent-reported improvement rates in behavioral symptoms (CBD:THC 20:1)

Significant improvement

Moderate improvement

Worsened

Bar-Lev Schleider 2019n=188 · Observational

30%

54%

8%

Aran 2019n=60 · Observational

30%

31%

8%

Aran 2021 (RCT)n=150 · Controlled trial

Whole-plant extract > pure CBD > placebo

Key finding: The 2021 controlled trial found whole-plant extract (with small amounts of THC) outperformed pure CBD alone — suggesting minor cannabinoids or terpenes contribute to efficacy.

Aran et al. (2019, 2021), Bar-Lev Schleider (2019)

Cannabis and Autism Research

Israel has been a leader in medical cannabis research, and some of the most relevant data on cannabis and autism comes from Israeli research groups.

Aran 2019: Aran and colleagues at Shaare Zedek Medical Center published a prospective study of 188 children and adolescents with autism treated with cannabis oil. Most patients used a CBD-dominant preparation (CBD:THC ratio of 20:1). After 6 months of treatment, 30 percent of patients reported significant improvement in behavioral symptoms, 54 percent reported moderate improvement, and 8 percent reported worsening. The most commonly improved symptoms were seizures (if present), restlessness, and rage attacks. Quality of life improved for both patients and parents.

This study was observational, with no control group. But the sample size was large for an autism cannabis study, and the results were meaningful enough to generate substantial interest.

Bar-Lev Schleider 2019: This was an even larger observational study of 188 autism patients treated with medical cannabis in Israel. After 6 months, 155 patients remained in active treatment (suggesting tolerability), and among those assessed, approximately 30 percent reported significant improvement and 54 percent reported moderate improvement in overall symptoms. Quality of life, mood, and ability to perform daily activities all showed improvement. The most commonly reported side effects were restlessness and drowsiness.

Aran 2021 (double-blind trial): Perhaps most importantly, Aran and colleagues conducted the first randomized, double-blind, placebo-controlled crossover trial of cannabinoids for autism. The trial tested a whole-plant cannabis extract (CBD:THC 20:1) versus pure CBD and placebo in 150 participants. The results, published in Molecular Autism, found that the whole-plant extract improved behavioral disruptions compared to placebo, particularly disruptive behavior as rated by caregivers. Pure CBD was less effective than the whole-plant extract, suggesting that THC (even in small amounts) or other plant compounds may contribute to efficacy.

This is the highest-quality evidence to date. While the effect sizes were modest and not all outcomes reached statistical significance, the direction of effect and the comparison between whole-plant and pure CBD are informative.

The Endocannabinoid System and Autism

There is emerging evidence that the endocannabinoid system may be altered in autism, though this research is in early stages.

Several studies have found differences in peripheral endocannabinoid levels in autistic individuals compared to neurotypical controls. Karhson and colleagues (2018) found lower levels of anandamide in the blood of children with ASD compared to age-matched controls. Aran and colleagues (2019, in a separate paper) also reported altered serum endocannabinoid levels in ASD patients, with lower anandamide levels correlating with more severe behavioral symptoms.

Genetic studies have identified associations between variants in endocannabinoid system genes and autism risk, though these associations are small and not specific to the ECS.

In animal models of autism, manipulating the endocannabinoid system has produced changes in social behavior. CB1 receptor knockout mice show social deficits, and enhancing endocannabinoid tone through FAAH inhibition improves social behavior in some autism-like rodent models.

These findings are preliminary. They do not establish that endocannabinoid dysfunction causes autism. But they suggest that the ECS is involved in some of the neural circuits relevant to autism and that modulating the system could potentially influence behavioral outcomes.

CBD-Dominant Products: The Most Common Approach

Most families using cannabis for autism choose CBD-dominant products with minimal THC. This preference reflects several factors.

CBD is non-intoxicating, which makes it more acceptable to parents and clinicians. The idea of giving a psychoactive substance to a child with developmental differences raises immediate concerns, and avoiding significant THC exposure addresses the most prominent of those concerns.

CBD has a favorable safety profile in pediatric use, established through the Epidiolex trials for epilepsy. The FDA approval of Epidiolex demonstrated that CBD is tolerable in children at doses up to 20 mg/kg/day, with liver enzyme elevation as the primary concern requiring monitoring.

Many children with autism have comorbid epilepsy (affecting approximately 20 to 30 percent), and CBD's antiseizure properties provide an additional rationale.

However, the Aran 2021 trial's finding that whole-plant extract (with small amounts of THC) outperformed pure CBD raises questions about whether CBD-only approaches are optimal. The contribution of low-dose THC, other cannabinoids (like CBG or CBC), or terpenes to the therapeutic effect is unknown but potentially significant.

Safety Concerns in Developing Brains

The most serious concern about cannabis use in autistic children is the effect on neurodevelopment. The endocannabinoid system plays critical roles in brain development, including neuronal migration, synapse formation, and circuit refinement. These processes are active throughout childhood and adolescence.

Studies of recreational cannabis use in adolescents have raised concerns about cognitive effects, including impacts on working memory, processing speed, and executive function. However, these studies involve THC-dominant products at doses much higher than the CBD-dominant, low-THC preparations used for autism, and they are confounded by other factors including self-selection, polysubstance use, and socioeconomic variables.

The specific risk of CBD-dominant products in the developing brain is less well characterized. Epidiolex trials in pediatric epilepsy patients have not revealed significant neurodevelopmental concerns, but the follow-up period is limited and the population (children with severe epilepsy) has significant baseline neurological compromise that makes it difficult to detect subtle cognitive effects.

The honest assessment is that we do not know the long-term neurodevelopmental consequences of chronic cannabinoid exposure in developing brains. This uncertainty does not automatically argue against use, particularly when the alternative is antipsychotic medications with their own developmental concerns. But it argues for caution, monitoring, and informed decision-making.

Ethical Considerations

Cannabis for autism raises ethical questions that do not arise as sharply in other contexts.

Autistic children cannot provide informed consent for their own treatment. Parents make medical decisions on behalf of their children, but the decision to use a minimally studied treatment in a developing brain carries particular weight.

The autism community is not monolithic in its views on cannabis. Some advocacy organizations support research and access. Others are cautious or opposed. Autistic self-advocates have raised concerns about the framing of behavioral symptoms as problems to be treated, particularly when those behaviors may be responses to sensory overload or communication frustration rather than pathology to be suppressed.

The power dynamics are real: children with severe autism who engage in self-injury and aggression are genuinely at risk, and their families are genuinely suffering. The severity of the situation justifies trying treatments beyond the standard options. But it also creates pressure to try anything that might help, which can lead to uncritical adoption of unproven treatments.

Parent Experience Data

Beyond the formal studies, parent forums, social media groups, and advocacy organizations have accumulated substantial anecdotal data on cannabis and autism.

The patterns reported by parents are consistent with the Israeli studies: improvement in agitation, aggression, and self-injury are the most commonly reported benefits. Sleep improvement is frequently mentioned and is often the first change parents notice. Some parents report improvements in communication and social engagement, though these are more variable and harder to measure.

Not all experiences are positive. Some parents report increased behavioral problems, particularly with products containing more than minimal THC. Others report initial improvement that wanes over time. And a significant number report trying cannabis and seeing no meaningful change.

These parent reports are valuable as signals but carry all the limitations of anecdotal evidence: selection bias, confirmation bias, concurrent treatment changes, and the natural variation in autism symptoms over time.

What Developmental Pediatricians Say

Most developmental pediatricians and child psychiatrists who work with autism remain cautious about cannabis. Their concerns center on the limited evidence base, the developing brain issue, and the unregulated nature of most cannabis products.

However, many acknowledge the inadequacy of current treatments for severe behavioral symptoms and express openness to CBD as a potential option after conventional treatments have been tried. The most common position is: we need better evidence, we understand why families are trying it, and we would rather have patients use it transparently under medical supervision than secretly without monitoring.

Some academic medical centers have begun to study cannabis for autism formally, including centers in Israel, the United States, and Australia. The results of these ongoing studies will substantially shape clinical practice.

The Regulatory Gap

In most jurisdictions, autism is not a qualifying condition for medical cannabis programs. This creates a regulatory gap where families must obtain products through other channels, which may mean adult recreational markets, hemp-derived CBD products with variable quality, or products obtained from other states or countries.

The lack of regulatory framework means that products are not standardized, dosing guidance is absent, and quality assurance is variable. Third-party testing is the closest thing to a safety net, and families should insist on it.

In some states and countries, advocacy groups have successfully lobbied for autism to be added to qualifying conditions for medical cannabis programs. This at least provides access to regulated products and clinical oversight, though it does not solve the evidence gap.

Practical Guidance for Families

For families considering cannabis for a child with autism, after consulting with their child's medical team, the following principles may help.

Start with CBD-dominant products. A CBD:THC ratio of 20:1 or higher is consistent with the products used in the Israeli studies. CBD-only products are a reasonable starting point.

Start with very low doses. Begin with 1 to 2 mg/kg/day of CBD, divided into two doses. Increase gradually over weeks based on response and tolerability. The maximum doses used in studies have been approximately 10 mg/kg/day.

Use third-party tested products. Quality assurance is essential when treating children. Products should have a certificate of analysis from an independent laboratory confirming cannabinoid content and the absence of contaminants.

Maintain current treatments while trialing cannabis. Do not stop antipsychotics, seizure medications, or other treatments to start cannabis. Changes to existing medications should only be made under physician supervision.

Track systematically. Use a standardized tool (even a simple daily rating scale for target behaviors) to track changes. Rate the target behaviors (aggression, self-injury, sleep) before starting cannabis and at regular intervals. This prevents the common problem of confirmation bias where parents perceive improvement because they expect it.

Monitor for side effects. Watch for increased sedation, changes in appetite, GI symptoms, and any worsening of behavior. Get baseline liver function tests and repeat after 3 months, consistent with Epidiolex monitoring protocols.

Set a time limit for the trial. Give the treatment 8 to 12 weeks at an adequate dose. If there is no meaningful improvement, discontinue. Continued use without benefit exposes the child to risk without reward.

The Bottom Line

Cannabis for autism sits at the intersection of desperate need, preliminary but promising evidence, and significant unknowns. The Israeli studies provide the strongest signal that cannabinoids, particularly CBD-dominant preparations, may help manage severe behavioral symptoms in autistic individuals. The Aran 2021 controlled trial is the first rigorous evidence supporting this, though it is a single study with modest effect sizes.

The safety questions about developing brains are real and unanswered. The ethical complexity of treating children who cannot consent is genuine. The inadequacy of current treatments for severe autism behaviors is also genuine.

For families who have exhausted conventional options and are considering cannabis under medical supervision, the evidence supports a cautious trial of CBD-dominant products at low doses with careful monitoring. This is not an endorsement of unregulated self-treatment. It is an acknowledgment that the evidence, while early, is pointing in a direction that warrants careful, supervised exploration.

More research is urgently needed. The families who are already using cannabis deserve evidence to guide their decisions. The children being treated deserve the safety of rigorous study. And the broader autism community deserves honest answers about what works, what does not, and what we do not yet know.

This article is for informational purposes only and does not constitute medical advice. Consult your healthcare provider before making any changes to your treatment plan.

The Bottom Line

Evidence review of cannabis for autism covering family context, Israeli studies, ECS alterations, CBD-dominant approach, developing brain safety, ethics, and practical guidance. Context: 1 in 36 children; risperidone/aripiprazole FDA-approved for irritability but significant side effects (weight gain, metabolic syndrome, tardive dyskinesia); 40-80% sleep disturbance; families seeking alternatives from exhaustion. Israeli studies: Aran 2019 — 188 children, CBD:THC 20:1, 30% significant + 54% moderate improvement, 8% worsening; Bar-Lev Schleider 2019 — 188 patients, similar results; Aran 2021 Molecular Autism (first double-blind RCT) — whole-plant CBD:THC 20:1 extract improved behavioral disruptions vs placebo, pure CBD less effective than whole-plant. ECS alterations: Karhson 2018 — lower anandamide in ASD children vs controls; Aran — altered serum endocannabinoids correlating with severity; CB1 knockout mice show social deficits; FAAH inhibition improves social behavior in autism-like models. CBD-dominant: non-intoxicating, pediatric safety established via Epidiolex (up to 20mg/kg/day); 20-30% comorbid epilepsy adds rationale; BUT Aran 2021 suggests whole-plant > pure CBD. Developing brain: ECS roles in neuronal migration, synapse formation, circuit refinement; adolescent THC cognitive concerns; CBD-specific long-term effects unknown; honest uncertainty. Dosing: start 1-2mg/kg/day CBD, divide BID; max ~10mg/kg/day; third-party tested; baseline LFTs; 8-12 week trial limit.

Frequently Asked Questions

Does CBD help autism symptoms?

Preliminary evidence suggests it can help behavioral symptoms in some children. Israeli observational studies (Aran 2019, Bar-Lev Schleider 2019) found approximately 30% significant improvement and 54% moderate improvement in behavioral symptoms with CBD-dominant products (CBD:THC 20:1). The first controlled trial (Aran 2021, Molecular Autism) found whole-plant CBD:THC 20:1 extract improved behavioral disruptions versus placebo, though effect sizes were modest. However, 8% reported worsening, and these were largely observational studies.

Is CBD or whole-plant cannabis better for autism?

The Aran 2021 controlled trial found that whole-plant cannabis extract (CBD:THC 20:1) outperformed pure CBD for behavioral disruptions. This suggests that even small amounts of THC or other plant compounds (minor cannabinoids, terpenes) may contribute to efficacy. However, most families start with CBD-only products due to concerns about giving a psychoactive substance to a child with developmental differences. The FDA-approved safety profile of CBD in children (via Epidiolex trials) adds confidence for the CBD component.

Is it safe to give cannabis to a child with autism?

This is the central uncertainty. The endocannabinoid system plays critical roles in neurodevelopment (neuronal migration, synapse formation, circuit refinement). CBD-dominant products appear well-tolerated based on Israeli studies and Epidiolex safety data, but long-term neurodevelopmental effects are unknown. The honest assessment: we do not know the long-term consequences of chronic cannabinoid exposure in developing brains. This uncertainty argues for caution, monitoring, baseline liver tests, and informed decision-making — not necessarily against use when alternatives (antipsychotics) have their own developmental concerns.

What is the right dose of CBD for a child with autism?

Based on the Israeli studies, start with 1-2 mg/kg/day of CBD, divided into two doses. Increase gradually over weeks based on response and tolerability. Maximum doses used in studies were approximately 10 mg/kg/day. Use third-party tested products with certificates of analysis. Maintain current medications while trialing cannabis. Get baseline liver function tests and repeat after 3 months. Set an 8-12 week time limit — if no meaningful improvement, discontinue.

What autism symptoms does cannabis help most?

The Israeli studies report the most improvement for agitation, rage attacks, self-injury, and restlessness. Sleep improvement is frequently the first change parents notice and is consistently reported. Some parents report improvements in communication and social engagement, though these are more variable and harder to measure. Seizures (comorbid in 20-30% of ASD) also improved when present. Not all experiences are positive — some report worsening, particularly with higher THC content.

Do doctors support using cannabis for autism?

Most developmental pediatricians remain cautious but increasingly acknowledge the inadequacy of current treatments for severe behavioral symptoms. The most common position: we need better evidence, we understand why families are trying it, and we prefer patients use it transparently under medical supervision rather than secretly without monitoring. Some academic centers (Israel, US, Australia) are now formally studying cannabis for autism. Autism is not a qualifying condition for medical cannabis in most jurisdictions, creating a regulatory gap.